Stay updated with breaking news from Eqrx Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Two original papers in Nature highlight the discovery and translational implications of RMC-7977, a RAS multi-selective tri-complex inhibitor that exhibits unprecedented anti-tumor activity in...
09.11.2023 - Acquisition Expected to Add Approximately $1.1 Billion in Net Cash to Revolution Medicines’ Balance Sheet, Supporting Late-Stage Development of RAS(ON) Inhibitor Investigational Drugs Sandra Horning, M.D., Joins Revolution Medicines' Board of ... Seite 1
REDWOOD CITY, Calif. and CAMBRIDGE, Mass., Nov. 08, 2023 -- Revolution Medicines, Inc. , a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, and EQRx, Inc. ,...
On Target to Outsmart Cancer November 6, 2023 © 2023 Revolution Medicines ...
EQRx, Inc. (NASDAQ:EQRXW – Get Free Report) was the recipient of a significant growth in short interest in the month of October. As of October 15th, there was short interest totalling 5,500 shares, a growth of 5.8% from the September 30th total of 5,200 shares. Based on an average daily volume of 24,200 shares, the […]